

Impact of *Candida* species colonization and azoles resistance in a neonatal intensive care unit



Daniela Maria Geraci*, Davide Vecchio, Giorgio Graziano, Laura Saporito, Vincenzo Insinga, Carmelo Massimo Maida, Maria Valeria Torregrossa, Francesco Vitale, Giovanni Corsello, Mario Giuffrè
 Department of Sciences for Health Promotion and Mother-Child Care "G. D'Alessandro", University of Palermo, Via del Vespro 133, 90127 Palermo, Italy; * e-mail address: danielamaria.geraci@unipa.it

INTRODUCTION AND PURPOSE

Candida species are among the top 10 most frequently isolated nosocomial bloodstream pathogens in Europe. In particular, in neonatal intensive care units (NICUs) *Candida* infections are an emerging concern because of the increasing incidence, the related high morbidity and mortality rates reported. Moreover, the epidemiology of *Candida* infection rapidly changed in these years leading to the selection of less sensitive strains and species. Surveillance studies are mandatory to identify the local distribution of species, their antifungal susceptibility profiles and the emergence of resistance strains.

METHODS

From December 2012 we performed a cohort prospective surveillance study on *Candida* colonization in our NICU, collecting weekly nasal and rectal swabs. Swabs were placed on Sabouraud agar. *Candida* growth on agar plates was confirmed by microscopic observation. Furthermore, *Candida* spp. was identified through *Candida* chromogenic agar (ChromAgar *Candida*, Laboratorios Conda) and API® 20C AUX (Biomérieux). The first isolated non-*C.albicans* *Candida* (NCAC) species from colonized patients were tested with the main antifungal agents (YeastOne® Y010 Thermo Fisher Scientific) and the obtained MIC values were read according to CLSI..

RESULTS

From December 2012 to June 2016 we enrolled 874 neonates and analyzed respectively 2014 nasal and rectal swabs. 20/2014 (0,99%) of nasal swabs and 128/2014 (6,35%) of rectal swabs tested positive for *Candida* spp. The species distribution is showed in the Graph 1. 89/874 (10,18%) neonates tested positive at least in one swab. 59 isolates of NCAC species were tested with the main antifungal agents. All the tested strains were susceptible to echinocandins and amphotericin B. The susceptibility patterns for azoles are shown in the Table 1.




Table 1: Azoles susceptibility patterns

Candida (C.) species	PZ			VOR			IZ			FZ			N° isolates
	MIC	CBPs	ECVs	MIC	CBPs	ECVs	MIC	CBPs	ECVs	MIC	CBPs	ECVs	
<i>C.famata</i>	≤0,008	S	N.I.	0,03	S	N.I.	0,03	S	N.I.	2	S	N.I.	3/3
<i>C.glabrata</i>	1	N.I.	WT	1	S	WT	0,5	DDS	WT	32	DDS	WT	5/11
	0,25	N.I.	WT	0,25	S	WT	0,12	S	WT	16	DDS	WT	1/11
	1	N.I.	WT	1	S	WT	2	R	WT	32	DDS	WT	4/11
	>8	N.I.	noWT	>8	R	noWT	>16	R	noWT	258	R	noWT	1/11
<i>C. guilliermondii</i>	≤0,008	S	N.I.	0,06	S	WT	≤0,015	S	N.I.	4	S	WT	1/4
	0,25	N.I.	N.I.	0,5	S	noWT	0,5	DDS	N.I.	16	DDS	noWT	1/4
	0,5	N.I.	N.I.	2	DDS	noWT	1	R	N.I.	64	R	noWT	1/4
	1	N.I.	N.I.	4	DDS	noWT	8	R	N.I.	64	R	noWT	1/4
	0,015	N.I.	WT	0,06	S	WT	0,03	S	WT	2	S	WT	30/41
<i>C.parasilosis</i>	≤0,008	S	WT	0,06	S	WT	≤0,015	S	WT	4	DDS	noWT	6/41
	0,015	N.I.	WT	0,06	S	WT	0,03	S	WT	64	R	noWT	2/41
	0,5	N.I.	WT	0,5	S	noWT	0,5	DDS	noWT	16	R	noWT	1/41
	2	N.I.	noWT	>1	R	noWT	>1	R	noWT	>32	R	noWT	2/41
		N.I.	noWT		R	noWT		R	noWT		R	noWT	

PZ=posaconazole, VOR=voriconazole, IZ=itraconazole, FZ= fluconazole, CBPs= clinical break-points, ECVs= epidemiological cutoff values
 N.I.= no interpretation available, S= susceptible, DDS= dose dependent suscepstible, R= resistant, WT= wild type, noWT=no wild type

REFERENCES:

CLSI M27-S4 Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Fourth Informational Supplement Pfaller, M. A., et al. "Multicenter study of anidulafungin and micafungin MIC distributions and epidemiological cutoff values for eight *Candida* species and the CLSI M27-A3 broth microdilution method." *Antimicrobial agents and chemotherapy* 58.2 (2014): 916-922.

CONCLUSIONS

Our study confirm the rule of surveillance in the prevention and control of *Candida* spp. healthcare related infections especially in an high risk ward such as NICU. In particular, in our NICU fluconazole prophylaxis is administered according to standard protocols from 2009. Antifungal susceptibility testes allowed to identify resistant and mutant strains whom acquired resistance so to obtain both clinical and epidemiological data promptly.